Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript March 20, 2024

Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. TRVI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good afternoon, and welcome to the Trevi Therapeutics Fourth Quarter and Year-End 2023 Earnings Conference Call. At this time, all participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded. Various remarks that management makes during this conference call about the company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company’s most recent quarterly report on Form 10-K, which the company filed with the SEC this afternoon.

In addition, any forward-looking statements represent the company’s views only as of today and should not be relied upon as representing the company’s views as of subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. I would now like to turn the conference over to Jennifer Good, Trevi’s President and CEO. Please go ahead.

Jennifer Good: Good afternoon, and thank you for joining our fourth quarter and year end 2023 earnings call and business update. Joining me today on this call are my colleagues, Lisa Delfini, Trevi’s Chief Financial Officer; and Dr. David Clark, Trevi’s Chief Medical Officer. Lisa and I have some prepared remarks, then we will open it up for questions. The fourth quarter of 2023 and start of 2024 was a productive time for Trevi with the initiation of three clinical studies. Let me provide a brief update on each of these trials. I will begin with our Phase 2a RIVER trial in Refractory Chronic Cough that was initiated in the fourth quarter of 2023. Refractory Chronic Cough or RCC is a debilitating disease that affects up to 10% of the adult population and is defined as a persistent cough lasting greater than eight weeks, despite a treatment for an underlying condition.

RCC is caused by cough reflex hypersensitivity in the central and peripheral nerves and has a significant impact on patients physically, psychologically and socially. With multiple drug failures in the space and a lack of any approved therapies for RCC in the U.S., there continues to be a significant unmet and urgent need for new potential treatments. The key point of differentiation for Haduvio and Refractory Chronic Cough is the mechanism of action, which works synergistically both centrally in the brain and peripherally in the lungs. We believe Haduvio’s central and peripheral mechanism has the potential to work in more patients and potentially have a stronger effect across a broader range of baseline cough counts than peripheral-only mechanisms like the P2X3 inhibitors.

RCC patients have been stratified for clinical trial purposes into three categories of frequency, very high, greater than 20 coughs per hour, high to moderate 10 to 19 cough per hour and low frequency coughers. The very high and high to moderate frequency coughers are all considered as having severe cost by the KOLs. The P2X3 to date only demonstrated statistical significance in the very high cough counters and have not shown successful results in the cough frequency of 10 to 19 cough per hour. We believe that based on the data from our IPF cough trial, which showed a strong drug effect across all baseline cough counts and the drug central and peripheral mechanism of action that Haduvio has the potential to work in patients broadly across varying cost frequencies.

When you look at the RCC patient distribution, 44% of the patients are estimated to have moderate to high cough frequency whereas only 29% are estimated to have very high cough frequency. So there’s potential Haduvio may address close to three-fourth of the RCC market, whereas P2X3s may only be effective in less than a third of the market. On to the details of our RCC trial, which is the standard design across several cough trials run to date. The RIVER trial is a Phase 2a double-blind randomized, placebo-controlled, two-period crossover study evaluating the reduction of cough in approximately six patients. These patients will be randomized with a one-to-one stratification between those with 10 to 19 coughs per hour and those with greater than 20 coughs per hour.

Each treatment period will last three weeks separated by a three-week washout period. Patients on Haduvio will have the dose titrated weekly from 27 milligrams up to 108 milligrams twice daily across the dosing period. The primary efficacy endpoint is the relative change in the 24-hour cost frequency at day 21 from treatment period baseline for Haduvio compared to placebo as measured by an objective cost monitor. The study will also explore secondary endpoints, including patient-reported outcome measures for cough and quality of life. We are excited to have initiated this study and expect to have substantially all the sites activated by the end of this month. We continue to expect top line data from this study in the second half of this year.

Next, an update on our lead program in idiopathic pulmonary fibrosis or IPF chronic cough. IPF is a serious end-of-life disease. Chronic cough is reported by approximately 85% of patients suffering from IPF and have similar significant physical, psychological and social impacts to that of RCC. But may also be a risk factor that plays a role in the progression of IPF. The constant lung injury micro tears and potential inflammation caused by persistent coughing may lead to worse health outcomes for patients such as increased respiratory hospitalizations, mortality or need for transplant. With no currently approved treatment options for chronic cough and IPF, patients and providers have an urgent need for new therapies. While there are a lot of ongoing development programs in IPF, current and in-development therapies have not shown an impact on chronic cough, one of the primary complaints of these patients, elevating the unmet need.

At the end of 2023, we initiated a Phase 2b study in chronic cough in IPS, the CORAL study. CORAL is a four arm Phase IIb dose-ranging trial that will study three active doses of Haduvio and placebo. The study is a six-week trial in approximately 160 patients. We plan to conduct this study in multiple countries and sites to be able to complete enrollment in a timely manner. Site activations are moving along in multiple countries and enrollment is in early stages. We reconfirm our guidance for this study for top line data in the first half of 2025, assuming no changes from our sample size reestimation results, which are expected in the second half of this year. And lastly, we initiated dosing of the final part of the human abuse potential or HAP study in January of this year.

The final portion of the HAP study is a randomized, double-blind, double-dummy five way crossover design to determine the abuse potential of three doses of oral nalbuphine relative to the selected dose of IV butorphanol and placebo. The primary objective is to evaluate the likability of nalbuphine as compared to both placebo and butorphanol, and the primary endpoint is a drug-liking vast scale. Recall that parenteral nalbuphine is unscheduled by the DEA. This study is moving along nicely, and we have passed the 50% enrollment mark. We continue to expect top line data from this study in the second half of this year as well. As you can see, it is a busy time clinically for Trevi, and we believe the data from these trials will be important to inform the development path forward for Haduvio and chronic cough conditions.

We are motivated by the potential to offer an effective treatment to patients with these serious conditions and chronic costs. I will now turn it over to Lisa to review our financial results, then we will open it up for any questions you may have.

Lisa Delfini: Thank you, Jennifer, and good afternoon, everyone. The full financial results for the 3 months ended December 31, 2023, can be found in our press release issued ahead of this call and our 10-K, which was filed with the SEC today after the market closed. For the fourth quarter of 2023, we reported a net loss of $7.8 million compared to a net loss of $5.5 million for the same quarter in 2022. R&D expenses were $6.5 million during the fourth quarter of 2023 compared to $4.3 million in the same quarter of 2022. The increase was primarily due to increased clinical trial costs in our Phase 2b CORAL trial and our Phase 2a RIVER trial, both of which were initiated in the fourth quarter of 2023. G&A expenses have remained essentially flat at $2.4 million during the fourth quarter of 2023 compared to $2.3 million in the same period of 2022.

We take a very disciplined approach to cash management and as a result, while R&D expenses increased as we are starting up four clinical trials. G&A expenses have remained consistent. Other income net was $1.1 million in both the fourth quarter of 2023 and 2022 and primarily consists of interest income on our cash balances, offset by any interest expense. We paid off our term loan in May of 2023, so interest expense was de minimis in the fourth quarter of 2023. As of December 31, 2023, our cash, cash equivalents and marketable securities totaled $83 million compared to $120.5 million as of December 31, 2022. Our cash runway guidance that we will have cash, cash equivalents and marketable securities into 2026 remains unchanged, and we believe is enough to fund all of the trials Jennifer just discussed and gives us good cash runway after the last readout.

In 2024, we expect average cash burn of about $9 million to $12 million per quarter and our fully diluted shares outstanding at December 1, 2023 is $114.5 million. This concludes our prepared remarks. I’ll now turn the call back over to the operator for Q&A.

See also 20 Countries With the Highest Tariffs and Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks.

Q&A Session

Operator: We will now begin the question-and-answer session. [Operator Instructions] Our first question comes from Leland Gershell with Oppenheimer. Please go ahead.

Leland Gershell: Good afternoon and thanks for taking our questions. Two from us. First, with respect to IPF did the CORAL design. Just wanted to have clarity on the primary endpoints. You’re testing three dose levels and then you have placebo. So will that primary endpoint in terms of 24 hour call frequency be the aggregate cough frequency across all three doses versus placebo or would it be to analyze on an individual basis with each dose level versus placebo? Thank you.

Jennifer Good: Go ahead, David.

David Clark: So Leland, thank you very much for the question. So the analysis will be per dose level. So high dose, mid dose, low dose, all compared independently with placebo. It’s important for us to get a good feel for dose response and that analysis allows us to do that.

Leland Gershell: Okay. Thanks. That’s very helpful. And then my other question, just wondering, maybe Jennifer, if you could comment on the recently published data from a short-term trial of low-dose controlled morphine used in the IPF offsetting, which has shown a 40% reduction in cough relate to placebo. But in the context of the fact that it was only a two-week trial and then, of course, morphine versus nalbuphine? Thank you.

Jennifer Good: Yeah. It’s a good question. The PAciFy trial, which was run in the U.K. I think, Leland, our takeaway was — it wasn’t surprising it worked. We believe in the mechanism. We think the opioid pathway works. But we also believe that the synergistic effect of working at both kappa and mu (ph) of our drug is important. And I think that’s why you see a 40% reduction from morphine and a 76% reduction or 74% reduction on nalbuphine. So we always thought it would work and we thought our drug would likely work better. I think the other challenge morphine has just practically is because of the respiratory depression, they are dose limited. They have to keep dose at very low doses. So that’s always going to sort of hinder where they can go with that.

Leland Gershell: Okay. Thanks very much for the added information.

Jennifer Good: Thank you.

Operator: The next question comes from Thomas Smith with Leerink Partners. Please go ahead.

Unidentified Participant: Hi. This is [indiscernible] on for Tom Smith. Congrats on the progress you made in 2023. We have a couple of questions. So the first one, you plan to conduct a sample side estimation for the CORAL trial. Can you walk us through the rationale and deposit behind the sample side as mentioned? And can you also remind us again on the number of targeted clinical sites and the split between the U.S. and ex-U.S. sites?

Jennifer Good: Yeah. I’m going to let David do this.

David Clark: Yeah. No. Thank you very much for the question. So the rationale is really to protect the study. We believe we’ve seen a very clinically relevant effect, as we’ve described in the Phase 2a study. So we want to be protected from the situation where the estimates that we have for the effect size going into the CORAL study we’ve assumed a 36% effect size. We believe we’ve been appropriately conservative compared to the placebo corrected more than 50% effect size from — that we saw in the Phase 2a study. But we wanted to protect ourselves from the situation where the effect size could still be clinically relevant because, as you know, from experts of this field 20% to 30% effect size on objective cough is believed to be clinically relevant.

So if we have and what we’ve done with the powering and the SSRE supports this is, if we have an effect size which is not as large as we saw in the Phase 2a, but it’s still clinically relevant, for example, 25%, we can detect that with an increased sample size.

Unidentified Participant: Got it.

Jennifer Good: Yeah. I would just add too, David, there hasn’t been a lot of work done in this area, right? There was one other good sized study in our small CANAL study. Everything else has failed or been too little. So you’re powering with not a lot of information. So it made sense, I think. Do you want to take this question too, a number of targeted sites and do you ask ex-U.S.?

David Clark: Yes. So we’ll be approximately 60 sites or so our plan for the CORAL study. And right now, the majority of those sites, they’re ex-U.S. So they’re primarily in the EU and U.K. We also have sites starting up in Australia in other regions, so Australia and Chile and Canada. Those are the main regions and countries we’re in at the present time and planning.

Unidentified Participant: Got it. Very helpful. And one last question, do you have an end of Phase 2 meeting with the FDA for Haduvio in prurigo nodularis and what’s the feedback from the meeting and the progress on partnership discussion? Thank you.

Jennifer Good: No. We have — yeah. No, Ut’s a good question. We have not yet filed a request for an end of Phase 2 meeting as you can tell from late in the year, David and his team were sort of flat out getting these studies up and running. We’ve got one more, we want to get running. And we’re sort of buttoning down all the reports and writing what we need to. But sometime a share, we’ll file for an end of Phase 2 meeting. It just hasn’t been a priority. So eventually, we’ll get there. We have not done so yet.

Unidentified Participant: Got it. Thank you so much.

Jennifer Good: Yeah. Thank you for the questions.

Operator: The next question comes from Serge Belanger with Needham & Company.

Serge Belanger: Hi. Good afternoon. Thanks for taking the question. I guess for Jennifer and David, just curious what kind of takeaways or KOL feedback you’ve gotten following the FDA adcom for Merck P2X3 candidate and the second CRL. Just curious if there’s been any change regarding the approach to clinical development or how they view the market opportunity for refractory chronic costs? Thanks.